Advanced Search

 

Study ID Status Title Patient Level Data
INO102141 Completed A two-centre, randomised, double-blind, double-dummy, placebo-controlled, 3-period cross-over study to evaluate the effect of treatment with repeat doses of GW274150 on the allergen-induced late asthmatic response in subjects with mild asthma.
INT 2767 Completed Interaction Study of 975mg Aspirin Given at Steady State of 10mg/sc SR90107A/Org31540 in Healthy Male Subjects
INT 3012 Completed Influence of Forced Diuresis on the Pharmacokinetics of Org31540/SR90107 After a Single Dose of 10 mg s.c. of Org31540/SR90107A in Healthy Male Subjects
INT3933 Completed Assessment of pharmacokinetic and pharmacodynamic drug interactions between ORG31540/SR90107A and digoxin in healthy male subjects
INT-CAR-13 Completed Effect of carvedilol as compared to an ACE-inhibitor (enalapril) on hypertension and “quality of life” related well-being.
IP2107882 Completed A single-centre, randomized, double-blind , placebo controlled, dose escalating cross-over study to evaluate the safety, tolerability and pharmacokinetics of single inhaled doses of GSK610677 and placebo in healthy male subjects
IPA101985 Completed A two-centre, randomised, double-blind, placebo-controlled, 2-period cross-over study to evaluate the effect of treatment with repeat doses of inhaled GSK256066 on the allergen-induced late asthmatic response in subjects with mild asthma
IPC101939 Completed A randomised, double-blind, placebo-controlled study to investigate the safety and tolerability of inhaled GSK256066 in mild to moderate COPD patients
IPC103711 Completed A double blind, placebo controlled, repeat dose study to compare the effectiveness of two doses of GSK256066 with placebo in reducing lung inflammation following segmental LPS challenge in healthy volunteers
IPR101987 Completed A 14 day, randomised, double blinded, placebo-controlled 2-way crossover trial of repeat doses of intranasal GSK256066 and placebo in an environmental exposition unit (Vienna Challenge Chamber) in subjects with seasonal allergic rhinitis (SAR)
IPR107498 Completed An 8 day, randomised, double blinded, placebo-controlled 2-way crossover trial of repeat doses of intranasal GSK256066 and placebo in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis (SAR)
IPR109764 Completed A randomised, open, placebo-controlled 5-way crossover trial of single doses of intranasal GSK256066 in subjects with seasonal allergic rhinitis (SAR).
IPR110723 Completed An 8 day, randomised, double blind, 3-way crossover trial of repeat doses of intranasal GSK256066 and fluticasone propionate in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis (SAR) Study Listed on ClinicalStudyDataRequest.com
IPR110982 Completed A randomised, double blind, 2-way crossover trial of 8 days repeat dosing with intranasal GSK256066 and azelastine hydrochloride in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis (SAR)
ISO105774 Completed Single-blind, placebo-controlled, randomized study testing single ascending doses of GSK369796 in healthy subjects
ITI101711 Completed A Dose Ranging Trial for the Evaluation of the Safety, Tolerability and Efficacy of Odiparcil in the Prevention of Venous Thromboembolism following Total Knee Replacement Surgery
ITZ111682 Completed A Single Dose, Randomized Study to Assess the Relative Bioavailability of Two Formulations and Food Effect on GSK1265744 in Healthy Male and Female Subjects
ITZ111839 Completed A Phase I, open label crossover study to evaluate the effect of etravirine on GSK1265744 pharmacokinetics in healthy adult subjects (ITZ111839)
K91-007 Completed To compare the bioavailabilities of the clinical trial and production formulations of ondansetron tablets (8 mg) for post-operative nausea and vomiting.
KG2104940 Completed A double-blind, randomized, placebo-controlled, repeat dose study to compare the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK189075 with GW869682 in subjects with type 2 diabetes mellitus
KG2105255 Completed A Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment Naïve Subjects.
KG2110243 Completed A Two-Week, Randomized, Double-Blind, Repeat-Dose, Parallel-Group Study to Evaluate the Safety and Tolerability of Metformin > 2000mg Co-Administered with Either GSK189075 500mg BID or GSK 189075 750mg BID to Subjects with Type 2 Diabetes Mellitus
KG2110375 Completed A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
KGW108201 Completed An exploratory study to evaluate weight loss, body composition changes, food intake and urine glucose excretion in healthy obese subjects over 8 weeks of dosing with GSK189075, GW869682 versus placebo
KGW111083 Completed A double-blind, randomized, 6-sequence, 3-period crossover drug-drug interaction study to evaluate the pharmacokinetics of WELLBUTRIN SR (bupropion) and GSK189075 when co-administered or administered alone in healthy male volunteers

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.